Macrolides are used to treat various inflammatory diseases owing to their immunomodulatory properties; however, little is known about their precise mechanism of action. In this study, we investigated the functional significance of the expansion of myeloid-derived suppressor cell (MDSC)-like CD11b 
Introduction
Macrolides have immunomodulatory properties in addition to their antibacterial effects [1, 2] . Indeed, previous clinical trials have shown that macrolides exhibit clinical benefits for various pulmonary diseases, including diffuse panbronchiolitis [3] , chronic obstructive pulmonary disease [4] , acute respiratory distress syndrome [5] , cystic fibrosis [6] , and non-cystic fibrosis bronchiectasis [7] . However, the precise mechanism underlying their favorable immunomodulatory effects remains largely unknown. Previous studies of macrolides have focused on their in vitro effects on isolated cells, such as immune cells, epithelial cells, endothelial cells, and fibroblasts [8] . In particular, macrolides inhibit the production of pro-inflammatory cytokines [9] ; however, the effects of macrolides on specific immune cell populations have not been examined. We hypothesized that the immunomodulatory properties of macrolides are physiological in origin, as they exhibit globally beneficial effects for various inflammatory diseases with different pathogenesis.
Myeloid-derived suppressor cells (MDSCs), a heterogeneous population of myeloid progenitors, are expanded in various diseases, including cancer, bacterial and parasitic infections, acute and chronic inflammation, sepsis, transplantation, and autoimmunity, and can potently suppress T-cell responses [10] [11] [12] . In mice, MDSCs express both CD11b and Gr-1, whereas human MDSCs mainly express Lineage 
CD33
+ , but lack markers homologous to mouse Gr-1 [10, 11] . Here, we present evidence that clarithromycin (CAM), a 14-membered macrolide, expands the immunosuppressive CD11b 
Results

Clarithromycin expands the CD11b
+
Gr-1 + cell population
We first examined whether macrolides, in this case CAM, could modulate immune cell populations in wild-type (WT) mice. Naive WT mice were intraperitoneally administered CAM daily for 3 days, and single-cell suspensions prepared from the spleen and lungs were analyzed by flow cytometry on the day after the last injection. We did not detect significant differences in the numbers of NK1.1 + , B220 + , CD4 + , and CD8 + lymphocytes in both the spleen and lungs between vehicle-and CAM-treated mice (Fig 1A and 1B) . Conversely, CAM administration markedly expanded the splenic and lung CD11b + Gr-1 + cell population in naive mice (Fig 1C-1E ). This significant increase in CD11b + Gr-1 + cell number was also observed after oral administration of CAM for 2 weeks (Fig 1F and 1G) . Next, we intraperitoneally injected CAM at various doses daily for three consecutive days and analyzed cell expansion 24 h after the last injection. As expected, CAM administration increased the CD11b The lungs were harvested from mice administered CAM daily for three consecutive days 24 h after the last CAM injection and stained with Gr-1 antibody. Of note, only Gr-1 + immunostaining was used because a previous flow cytometry analysis revealed that nearly all Gr-1 + cells in the lungs after CAM treatment were CD11b + cells (Fig 1D) . Interestingly, Gr-1 + cells increased markedly after CAM treatment and were mainly located in the extravascular space of the lungs (i.e., the lung parenchyma or interstitium) (S2 Fig) .
CAM-treated CD11b
+
Gr-1 + cell population exhibits immunomodulatory properties
To further characterize the CAM-treated CD11b + Gr-1 + cell phenotype, we performed a microarray analysis with sorted splenic CD11b + Gr-1 + cells obtained from vehicle-and CAMtreated mice. We detected a 310-fold increase in the expression of arginase-1 expression, which is a key enzyme inhibiting T cell proliferation and an MDSC marker (Fig 2A) . We confirmed that both intraperitoneal injection and oral administration of CAM induced arginase-1 mRNA expression in splenic CD11b (Fig 2B) . In addition, immunostaining analysis confirmed that Gr-1 + cells produce arginase-1 in the lungs of CAM-treated mice (Fig 2C) . We next measured the concentration of splenic nitric oxide (NO), a crucial parameter for MDSC biology and identification [13] . The NO concentration was significantly higher in the spleen of CAM-treated mice than in that of vehicle-treated mice (Fig 2D) .
To further investigate the function of CAM-treated CD11b [11] , CD80 [11] , CD115 [11] , and CX3CR1 [18] . There were no dramatic differences in the expression of these markers, but CD244 and CTLA-4 expression tended to be slightly higher in CAM-treated CD11b (Fig 2E) .
To further investigate the functions of these cell populations in vitro, bone marrow-derived macrophages (BMDMs) were co-cultured with CAM-or vehicle-treated CD11b + Gr-1 + cells stimulated with LPS (i.e., with cell-cell contact), and cytokine secretion was assessed 12 h later. Notably, CAM-treated CD11b + Gr-1 + cells suppressed pro-inflammatory cytokine production (TNF-α and IFN-γ) and increased anti-inflammatory IL-10 levels (Fig 2F-2H mice were subjected to LPS-endotoxin shock. Pretreatment with CAM significantly increased survival ( Fig 3A) . Moreover, TNF-α and IFN-γ serum levels were significantly lower in CAMtreated mice 12 h after LPS injection, and IL-10 levels were significantly higher than those in vehicle-treated counterparts (Fig 3B-3D (Fig 3E and 3F) , we used an anti-Gr-1 (including Ly-6G
and Ly-6C) antibody to deplete this cell population. The improved survival observed for CAM treatment in the LPS-shock model was reversed by Gr-1 + cell depletion at 24 h before LPS treatment ( Fig 3H) . In addition, we obtained similar results when the Gr-1 + cell population was depleted 1 h before the first CAM treatment (i.e., from the beginning of CAM treatment) (Fig 3I) . These results indicate that the CAM-treated Gr-1 population has protective effects in this model. Next, we adoptively transferred CD11b (Fig 3J) and PBS control injections (S9 Fig) , and was associated with decreased TNF-α and IFN-γ and increased IL-10 serum levels (Fig 3K-3M In particular, we used a clinically isolated strain of Streptococcus pneumoniae (serotype 3) that harbors penicillin and macrolide resistance genes, although the strain was classified as a penicillin-intermediate resistant S. pneumoniae (PISP), as described in the Materials and Methods section and S1 Table. CAM treatment significantly improved survival when compared to that of vehicle-or ampicillin (ABPC)-treated mice (Fig 5A) , whereas JOS treatment did not improve survival (S11 Fig) . Interestingly, both CAM and ABPC significantly reduced total cell counts in bronchoalveolar lavage fluid (BALF) as compared to those in vehicle-treated mice (Fig 5B) , as well as the bacterial load in lungs 18 h after infection ( Fig 5C) . Blood cultures showed lower bacterial loads in CAMtreated mice than in vehicle-and ABPC-treated mice, but the differences were not significant ( Fig 5D) . Moreover, a histopathological examination of the lungs 18 h after pneumococcal infection indicated that both CAM and ABPC ameliorated white blood cell recruitment (mainly neutrophils), alveolar wall thickening, and edema when compared to those of vehicletreated mice ( Fig 5E) . Furthermore, IFN-γ levels were significantly suppressed in the BALF and serum in CAM-treated mice as compared to vehicle-treated and ABPC-treated mice, respectively, whereas IL-10 was markedly increased in both the BALF and serum of CAMtreated mice (Fig 5F-5I) . Similarly, adoptive transfer of splenic CD11b Clarithromycin expands CD11b
Previous studies of post-influenza pneumococcal pneumonia have reported that IFN-γ production is detrimental to secondary bacterial infection [21, 22] ; thus, because our results showed that CAM and CAM-treated CD11b ) and WT mice were subjected to post-influenza pneumococcal pneumonia. We first confirmed better survival in vehicle-treated Ifng -/-mice than in vehicle-treated WT mice (Fig 5L) , consistent with previous results showing that Ifng -/-mice are resistant to post-influenza pneumococcal pneumonia [22] . We also observed slightly higher survival in CAM-treated Ifng -/-mice than in vehicletreated Ifng -/-mice and CAM-treated WT mice (Fig 5L) , suggesting that the protective effects of CAM in this model depend, at least in part, on suppression of IFN-γ production. Collectively, these data demonstrate that CAM improves the overall survival of mice with post-influenza pneumococcal pneumonia, at least in part via suppression of IFN-γ production by CAMtreated CD11b
Previous studies have indicated that type I IFN is also detrimental in a post-influenza pneumococcal pneumonia model using interferon-α/β receptor (IFNAR) knockout (Ifnar1 -/-mice, as well as WT mice treated with a CXCR4 antagonist (AMD3100). However, no differences were observed between these mice and WT controls (S13 Fig), indicating that IL-17, CCL2, CXCR4, and TLR/MyD88 signaling pathways are not involved in this process. The prokineticin family member Bv8 (also known as prokineticin 2 [Prok2]) was previously reported to induce CD11b + Gr-1 + cells in an autocrine and paracrine STAT3-dependent manner [24] . Notably, our microarray data identified that Bv8 (Prok2) was highly expressed (12.3-fold higher relative to WT mice) in splenic CD11b + Gr-1 + cells obtained from CAMtreated mice (Fig 2A) . A protein analysis of splenic cells after CAM treatment revealed higher Bv8 expression than that in vehicle-treated mice (Fig 6A) , as well as increased phosphorylated (p)-STAT3 (Fig 6B) . To investigate the role of Bv8 in CAM-induced CD11b + Gr-1 + cell induction, mice were administered an anti-Bv8 antibody at 4 days and 1 day before, and then during, the CAM treatment period (three consecutive days Macrolide administration causes substantial changes in the composition of the gut microbiota [25] . Accordingly, we hypothesized that the modulation of the gut microbiota by CAM might contribute to the expansion of CD11b + cell population appeared to increase following CAM treatment, the difference was not significant (p = 0.0699) ( Fig 7B) ; however, arginase-1 gene expression was markedly elevated in these cells after 7 days of CAM treatment compared to the baseline control measurements (Fig 7C) . These results suggest that human Lineage 
Discussion
In this study, we demonstrated that CAM stimulates the expansion of the immunosuppressive CD11b Clarithromycin expands CD11b + Gr-1 + MDSC-like cells population in mice, as they both exhibited a significant increase in arginase-1 mRNA expression levels following CAM treatment. Increasing evidence suggests that macrolides have immunomodulatory properties, beyond their antibacterial effects [1, 2] ; however, the overuse of these drugs for this purpose is criticized because the mechanism of action is unclear [26] . Therefore, the elucidation of their exact immunomodulatory effects is needed. Numerous in vitro studies have demonstrated that macrolides modulate the release of humoral factors from immune, epithelial, and other + cells from healthy volunteers before and 7 days after oral treatment with clarithromycin (CAM) (800 mg/day) (n = 6). Data are presented as the mean ± SEM.
ÃÃÃ p < 0.001 by the Mann-Whitney U-test. [30] . Many earlier studies found that IL-10 promotes survival in sepsis and endotoxin shock [31] [32] [33] , consistent with our results indicating beneficial effects of IL-10 in LPS-induced shock. IL-10 has been reported to have detrimental roles in post-influenza pneumococcal pneumonia [34, 35] ; however, another previous study found no significant differences in susceptibility to post-influenza secondary pneumococcal infection between WT and Il10 -/-mice [22] . We did not determine the detailed mechanisms underlying increased IL-10 levels in the post-influenza pneumococcal pneumonia model in the present study, but this should be evaluated in further studies. We also showed that CAM-treated CD11b + Gr-1 + cells distinctly suppressed IFN-γ production both in vitro and in vivo, corroborating earlier studies of the 14-membered ring macrolide erythromycin in a mouse model of influenza virus infection [36] . The significance of suppressed IFN-γ production in LPS-induced endotoxin shock was not evaluated in the present study; however, IFN-γ has been reported to be detrimental in LPS-endotoxin shock by hampering endotoxin tolerance [37, 38] . Considering these previous reports and our results indicating the partial restoration of IFN-γ production in macrophages co-cultured with CAMtreated Il10 -/-CD11b + Gr-1 + cells (Fig 4C) , we speculate that enhanced IL-10-mediated IFN-γ suppression by CAM would also protect against LPS-induced endotoxin shock. In terms of significance, a previous study indicated that IFN-γ production by CD4 + and CD8 + T cells in response to influenza virus infection enhanced susceptibility to secondary pneumococcal infection [22] . In addition, accumulating evidence indicates that CD11b + Gr-1 + cells suppress IFN-γ production by T cells [39, 40] and NK cells [41] . As such, we speculate that the suppression of IFN-γ production in these cells, as well as macrophages, by CAM treatment would have protective effects in post-influenza pneumococcal pneumonia. Consistent with this notion, we confirmed that exogenous administration of recombinant IFN-γ partially reversed the survival benefit in post-influenza pneumococcal pneumonia model mice. We also observed slightly greater survival in CAM-treated Ifng -/-mice than in vehicle-treated Ifng -/-mice and CAM-treated WT mice. These results suggest that the protective effects of CAM in this model at least partially depend on suppression of IFN-γ production. We speculate that, in addition to IFN-γ suppression, other mechanisms, such as increased IL-10, contribute to the protective effects of CAM in this model. Furthermore, we found that the STAT3/Bv8 axis is actively involved in the mechanism underlying CAM-induced CD11b + Gr-1 + cell expansion. Bv8 induces CD11b + Gr-1 + cells in an autocrine and paracrine STAT3-dependent manner [24] , and regulates CD11b + Gr-1 + celldependent tumor angiogenesis [42] . A Bv8 antagonist was found to inhibit angiogenesis and myeloid cell infiltration in mouse models of glioblastoma and pancreatic cancer [43] . These studies, in combination with our study, suggest that the STAT3/Bv8 axis is essential to myeloid cell recruitment, including that of CD11b Previous studies have clearly demonstrated that 14-and 15-membered, but not 16-membered macrolide antibiotics, can decrease pro-inflammatory cytokine and chemokine secretion [8, 19, 20] . Similarly, we observed expansion of CD11b Oral administration of 25-100 mg/kg CAM in mice is comparable to clinically achievable levels in humans [45] . As the area under the curve (AUC) was more than 2-fold higher for intraperitoneal administration of 10 mg/kg CAM than for oral administration of 10 mg/kg CAM (personal communication), we believe that the intraperitoneal administration of CAM at 100 mg/kg in the present study is clinically relevant for humans.
The overuse of macrolide antibiotics could result in the evolution of macrolide-resistant organisms. To address this concern, immunomodulatory macrolides lacking antimicrobial effects, e.g., EM900 and EM703, have been in development [46, 47] as a major human MDSC population. In addition, we observed upregulation of arginase-1 mRNA in the human MDSC population after oral administration of CAM, indicating that CAM likely expands immunosuppressive MDSC-like cells in humans. In the present study, peripheral blood was used to assess CAM-treated human MDSCs, but these effects could be evaluated with much greater clarity in lung or spleen cell populations, as in the model mice.
In the present study, we used an anti-Gr-1 antibody (RB6-8C5 clone, anti-Ly-6G and Ly-6C antibody) to deplete the Gr-1 + cell population, resulting in depletion of both monocyticand granulocytic-MDSC-like cell populations. This may not be a good approach for the depletion of MDSC-like cells owing to the lack of selectivity, i.e., myeloid cells such as neutrophils and monocytes/macrophages can also be depleted by treatment with the anti-Gr-1 antibody. Although several parameters have been suggested for distinguishing granulocytic-MDSCs from neutrophils [14] , they are insufficient [48] . 
Materials and methods
Mice
Male WT C57BL/6J mice (8-10 weeks old) were purchased from CLEA Japan, Inc. (Tokyo, Japan were purchased from CLEA Japan, Inc., and were kept in the germ-free facility at Keio University School of Medicine. Other mice were housed under specific pathogen-free (SPF) conditions.
Ethics statement
The present study was performed in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal experiments were approved by the Animal Care and Use Committee at the Keio University School of Medicine (Protocol No. 12110). The human study was approved by the Ethics Committee of Keio Center for Clinical Research in November 2012 (Protocol No. 20120250). All participants of the study (i.e., blood donors) were informed about the risks of participation in the study and written consent was obtained from all of them. All participants were adults and non-minors.
Preparation and injection of clarithromycin and other antibiotics
Clarithromycin (CAM) was kindly provided by Taisho Toyama Pharmaceutical Co., Ltd.
(Tokyo, Japan), and diluted with PBS containing 5% gum arabic. The CAM or vehicle solution (5% gum arabic in PBS) was intraperitoneally injected at 100 mg/kg daily throughout the course of the experiment. In oral administration experiments, the CAM and vehicle solutions were administered at 100 mg/kg by gavage daily for 14 days. The dose of CAM was determined based on preliminary experiments summarized in S1 Fig and previous reports [45, 50, 51] . Azithromycin (Sigma-Aldrich), josamycin (Sigma-Aldrich), and ampicillin (Sigma-Aldrich) were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) at 10 mg/mL and further diluted in sterile PBS. Antibiotics were administered in vivo at 100 mg/kg, 200 mg/kg, and 100 mg/kg, based on previous reports [51] [52] [53] [54] .
Flow cytometry and sorting
In mouse studies, single-cell suspensions were prepared for flow cytometry as follows; spleens and lungs were cut into small fragments and digested for 45 min at 37˚C with RPMI 1640 containing 0.05 mg/mL Liberase (Roche Diagnostics, Basel, Switzerland) and 250 U/mL DNAse I ( Stained cells were processed by flow cytometry using a BD FACS Aria II system (BD Biosciences) or MoFlo XDP (Beckman Coulter, Brea, CA, USA) and the data were analyzed using FlowJo 7.6.2 (Tree Star, Inc., Ashland, OR, USA).
Immunofluorescence
Lung tissue was fixed with 4% paraformaldehyde and embedded in paraffin. The lung sections were deparaffinized in xylene and rehydrated in a graded ethanol series, and antigen retrieval was performed by heating sodium citrate buffer at 95˚C for 20 min. Non-serum protein block (Dako) was applied for 30 min. Slides were then stained with rat anti-Gr-1 primary antibody (RB6-8C5; R&D Systems) or rabbit anti-arginase-1 primary antibody (ABS535; Merck, Kenilworth, NJ, USA) followed by Alexa Fluor 488-or Alexa Fluor 555-coupled secondary antibody, respectively (Invitrogen, Carlsbad, CA, USA). Sections were counterstained with DAPI (Vector Labs) and analyzed using an Axio Imager (Zeiss, Oberkochen, Germany).
In vivo antibody labeling
After mice were anesthetized by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (100 mg/kg), an APC-Cy7-CD45 antibody conjugate (0.4 μg/2 μL diluted in 100 μL of PBS) was administered 5 min before euthanasia together with heparin (10 IU/g). After 5 min, mice were exsanguinated and intratracheally injected with a PerCPCy5.5-CD45 antibody conjugate (0.4 μg/2 μL diluted in 100 μL of PBS). After an additional 5 min, the lungs were harvested and a lung single cell suspension was prepared, followed by staining with a PE-Cy7-CD45 antibody conjugate ex vivo.
Microarray analysis
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. The isolated RNA was quantified, and quality was assessed using an Agilent 2100 BioAnalyzer with the RNA Nano Chip (Agilent, Santa Clara, CA, USA). Then, 2 μg of total RNA was used to generate single-stranded antisense cDNA using the Ovation Biotin System (NuGEN Technologies, San Carlos, CA, USA) according to the manufacturer's instructions. Labeled targets were hybridized to Affymetrix MOE430 2.0 GeneChip microarrays (Affymetrix) for 16 h at 45˚C. The arrays were washed and scanned according to standard Affymetrix protocols. GeneSpring 12.0 (Silicon Genetics, Redwood City, CA, USA) was used for data analysis. Microarray data sets have been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus under accession number GSE81241.
Arginase activity
Splenic CD11b 
Nitric oxide measurement
The NO concentration in spleen extracts was determined using the Quantichrom Nitric Oxide Assay Kit (BioAssay Systems) according to the manufacturer's instructions.
T cell proliferation assay
CD3 + T cells were isolated from splenocytes by negative selection, using a magnetic cell sorting system (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). Sorted cells were washed and resuspended in 5 mL of PBS/0.1% bovine serum albumin (BSA). T cell proliferation assays were performed using the CellTrace CFSE Cell Proliferation Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Briefly, the sorted CD3 + T cells were incubated with CFSE for 20 min, washed, and then stimulated with anti-CD3 antibody (5 μg/mL) (BioLegend) and anti-CD28 antibody (1 μg/mL) (BioLegend). The CFSE-labeled CD3 + T cells were then co-cultured with sorted splenic CAM-treated or vehicle-treated CD11b 
Elastase activity assay
The Neutrophil Elastase Activity Assay Kit (Cayman, Ann Arbor, MI, USA) was used to measure elastase activity according to the manufacturer's instructions.
Myeloperoxidase activity assay
The Myeloperoxidase (MPO) Activity Assay Kit (Colorimetric) (ab105136; Abcam, Cambridge, UK) was used to measure MPO activity according to the manufacturer's instructions.
Phagocytic activity assay
The Phagocytosis Activity Assay Kit (IgG FITC) (Cayman) was used to measure phagocytic activity according to the manufacturer's instructions. 
Preparation of various types of
Culture of murine bone marrow-derived macrophages
Bone marrow cells were harvested from 8-10-week-old-male C57BL/6J mice by flushing the femur and tibia with RPMI 1640 medium. Recovered cells were then cultured in bone marrow cell medium (20% FCS, 30% L-cell supernatant, 2 mM L-glutamine, 1% penicillin/streptomycin, 0.25 μg/mL amphotericin B in RPMI 1640). Fresh bone marrow cell medium was added on day 3. On day 6, adherent cells were replated in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine, and 1% penicillin/streptomycin for use as BMDMs. On day 7, the medium was removed and BMDMs were cultured with or without CD11b 
Enzyme-linked immunosorbent assay
TNF-α, IFN-γ, and IL-10 levels were measured using a DuoSet ELISA Kit (R&D Systems) according to the manufacturer's instructions.
Lipopolysaccharide-induced endotoxin shock mice model
Mice received a single intraperitoneal (i.p.) injection of 50 mg/kg LPS (Escherichia coli O111: B5; Sigma-Aldrich). For CAM pre-treatment, mice were intraperitoneally injected with CAM (100 mg/kg) once daily for three consecutive days, followed by LPS challenge the day after the last injection of CAM. For the pharmacological depletion of Gr-1 + cells, mice received an i.p. injection of an antiGr-1 antibody (250 μg/mouse) (clone RB6-8C5; BioLegend) or isotype control antibody 24 h before LPS challenge or 1 h before starting CAM treatment (i.e., 73 h before LPS challenge). The antibody dose was determined according to our previous study [55] . 
Influenza virus and secondary Streptococcus pneumoniae infection in mice
Influenza virus A/H1N1/PR8/34 (PR8) was kindly provided by Dr. Hideki Hasegawa (National Institute of Infectious Diseases, Tokyo, Japan) [56] . The PR8 virus titer was measured by a plaque forming assay using Madin-Darby canine kidney (MDCK) cells (CCL-34; American Type Culture Collection).
S. pneumoniae was kindly provided by Dr. Kimiko Ubukata (Keio University, Tokyo, Japan). The strain was clinically isolated (serotype 3) and was both penicillin-and macrolideresistant, harboring penicillin resistance (penicillin binding protein [pbp1a, pbp2x, and pbp2b]) and macrolide resistance (mefA and ermB) genes. Detailed drug susceptibility testing of the strain is shown in S1 To establish the post-influenza secondary S. pneumoniae infection mouse model, mice were intranasally inoculated with five plaque-forming units (PFUs) of PR8. Seven days after PR8 infection, the mice were intranasally infected with 1 × 10 4 colony-forming units (CFUs) of S.
pneumoniae suspended in 50 μL of PBS. Mice were then intraperitoneally injected with CAM (100 mg/kg) diluted in PBS with 5% gum arabic or vehicle daily starting from 1 h after pneumococcal infection throughout the course of the experiment. Mice were monitored for survival for up to 5 days after pneumococcal infection. A 7-day interval between influenza infection and subsequent S. pneumoniae inoculation was used as a lethal model in the present study, based on previous studies [21, 57] . For IFN-γ administration, mice were intranasally inoculated with 16 μg/kg recombinant IFN-γ (PeproTech) or vehicle at 30 min and 24 h after pneumococcal infection. The dose of recombinant IFN-γ was determined according to a previous report [58] and survival was monitored for 7 days.
Bronchoalveolar lavage
Bronchoalveolar lavage fluid (BALF) was collected with 0.7 mL of saline, and total cell counts were determined [59] .
Bacterial load
Whole left lungs were harvested and homogenized with 1 mL of sterile PBS with 0.1% Triton X and serially diluted with sterile PBS. Equal volumes of each dilution of the lung homogenates and blood were applied to trypticase soy agar (TSA) plates containing 5% sheep blood (BD Trypticase Soy Agar II with 5% Sheep Blood; BD Diagnostics) and incubated overnight at 37˚C. After overnight incubation, bacterial colonies were counted and expressed as CFUs per mL of solution.
Histological analysis
Lung specimens harvested 18 h after pneumococcal infection were fixed with 4% paraformaldehyde. After dehydration and embedding in paraffin, 3-μm sections were stained with hematoxylin and eosin (H&E).
Protein extraction from whole lung tissues and immunoblotting
Whole lung tissues were homogenized using a Dounce tissue homogenizer on ice in RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific). Homogenates were centrifuged at 12,000 × g at 4˚C for 20 min, and the supernatants were collected and stored at −80˚C until use for protein analysis. Bicinchoninic acid (BCA) protein assays (Thermo Fisher Scientific) were used to measure the total protein concentration in lung homogenates.
Equal amounts (15-30 μg) of cell lysates were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Bio-Rad Laboratories), and the proteins were transferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories). After overnight incubation with antibodies against prok2 (Millipore, Billerica, MA, USA), STAT3, or p-STAT3 (both from Cell Signaling Technology, Danvers, MA, USA), the membrane was counterstained with horseradish peroxidase-conjugated rabbit IgG antibody and visualized with enhanced chemiluminescence detection reagents (GE Healthcare). Images were analyzed using ImageJ 1.45v (National Institutes of Health, Bethesda, MD, USA).
Analysis of anti-Bv8/Prok2 antibody treatment
The anti-Bv8 antibody was kindly provided by Genentech. Mice were intraperitoneally injected with the anti-Bv8 antibody (5 mg/kg) or control IgG at 4 days and 1 day before CAM treatment and once daily for three consecutive days during CAM treatment.
Quantitative real-time polymerase chain reaction
Total RNA was isolated from the lung or spleen using the RNeasy Mini Kit according to the manufacturer's instructions (QIAGEN). Total RNA was reverse-transcribed using the HighCapacity RNA-to-cDNA cDNA Kit (Life Technologies). Real-time quantitative polymerase chain reaction (PCR) was performed using SYBR Green chemistry on a 7500 Fast Real-Time PCR system (Applied Biosystems). The primer sequences for each target gene are provided in S2 Table.
Purification of human peripheral blood cells
Peripheral blood cells were isolated from healthy subjects. Red blood cells (RBCs) were removed from 40 mL of heparinized peripheral blood using Dextran T-500 (Pfizer). After removal any remaining RBC using ammonium-chloride-potassium (ACK) lysis buffer (Lonza, Basel, Switzerland), peripheral cells were stained with antibodies described above.
Statistical analysis
Data are expressed as the mean ± SEM and analyzed using the Mann-Whitney-U-test, Wilcoxon matched-pairs signed rank test, or ANOVA, followed by Tukey's tests for multiple comparisons. Log-rank tests were performed for survival studies. p < 0.05 was considered statistically significant. 
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